Empreu aquest identificador per citar o enllaçar aquest ítem:
http://hdl.handle.net/10609/93055
Registre complet de metadades
Camp DC | Valor | Llengua/Idioma |
---|---|---|
dc.contributor.author | Catalán Alonso, Maria José | - |
dc.contributor.author | Antonini, Angelo | - |
dc.contributor.author | Calopa Garriga, Matilde | - |
dc.contributor.author | Bajenaru, Ovidiu | - |
dc.contributor.author | Fàbregues, Oriol de | - |
dc.contributor.author | Mínguez Castellanos, Adolfo | - |
dc.contributor.author | Odin, Per | - |
dc.contributor.author | García Moreno, José Manuel | - |
dc.contributor.author | Pedersen, Stephen W. | - |
dc.contributor.author | Pirtosek, Zvezdan | - |
dc.contributor.author | Kulisevsky, Jaime | - |
dc.contributor.other | Hospital Clínico San Carlos | - |
dc.contributor.other | IRCCS Ospedale San Camillo | - |
dc.contributor.other | Hospital Universitari de Bellvitge | - |
dc.contributor.other | Carol Davila University of Medicine and Pharmacy | - |
dc.contributor.other | Vall d'Hebron Barcelona Hospital Campus | - |
dc.contributor.other | Complejo Hospitalario Universitario de Granada | - |
dc.contributor.other | Lund University | - |
dc.contributor.other | Hospital Universitario Virgen Macarena | - |
dc.contributor.other | University of Copenhagen | - |
dc.contributor.other | University Medical Centre Ljubljana | - |
dc.contributor.other | Universitat Oberta de Catalunya | - |
dc.date.accessioned | 2019-04-11T07:53:58Z | - |
dc.date.available | 2019-04-11T07:53:58Z | - |
dc.date.issued | 2017-07-02 | - |
dc.identifier.citation | Catalán, M.J., Antonini, A., Calopa, M., Bajenaru, O., Fàbregues, O. de, Mínguez-Castellanos, A., Odin, P., García-Moreno, J.M., Pedersen, S., Pirtosek, Z. & Kulisevsky, J. (2017). Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?. eNeurologicalSci, 8(), 44-53. doi: 10.1016/j.ensci.2017.06.004 | en |
dc.identifier.issn | 2405-6502MIAR | - |
dc.identifier.uri | http://hdl.handle.net/10609/93055 | - |
dc.description.abstract | Advanced Parkinson's disease (APD) is characterized by increased functional disability, caused by motor complications, the presence of axial symptoms, and emergent disease- and drug-related non-motor symptoms. One of the advanced therapies available is intrajejunal infusion of levodopa/carbidopa intestinal gel (LCIG); however, patient selection for this treatment is sometimes difficult, particularly because of overlapping indications with other alternatives. In recent years, strong evidence has supported the use of LCIG in treating motor fluctuations associated with APD, and several clinical studies provide emerging evidence for additional benefits of LCIG treatment in certain patients. This article provides an overview of the published literature on the benefits, limitations, and drawbacks of LCIG in relation to PD symptoms, the psychosocial impact of the disease, and the quality of life of patients, with the aim of determining candidates for whom treatment with LCIG would be beneficial. According to current evidence, patients with APD (defined as inability to achieve optimal control of the disease with conventional oral treatment), a relatively well-preserved cognitive-behavioral status, and good family/caregiver would count as suitable candidates for LCIG treatment. Contraindications in the opinion of the authors are severe dementia and active psychosis. | en |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | eNeurologicalSci | - |
dc.relation.ispartof | eNeurologicalSci, 2017, 8 | - |
dc.relation.uri | https://doi.org/10.1016/j.ensci.2017.06.004 | - |
dc.rights | CC BY-NC-ND | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | - |
dc.subject | non-motor symptoms | en |
dc.subject | Parkinson's disease | en |
dc.subject | enfermedad de Parkinson | es |
dc.subject | enfermetat de Parkinson | ca |
dc.subject | infusión intrayeyunal de levodopa/carbidopa | es |
dc.subject | infusió intraieiunal de levodopa/carbidopa | ca |
dc.subject | Intrajejunal infusion of levodopa/carbidopa | en |
dc.subject | intestinal gel | en |
dc.subject | gel intestinal | es |
dc.subject | gel intestinal | ca |
dc.subject | duodopa | ca |
dc.subject | duodopa | es |
dc.subject | duodopa | en |
dc.subject | motor symptoms | en |
dc.subject | síntomas motores | es |
dc.subject | símptomes motors | ca |
dc.subject | quality of life | en |
dc.subject | calidad de vida | es |
dc.subject | qualitat de vida | ca |
dc.subject | síntomas no motores | es |
dc.subject | símptomes no motors | ca |
dc.subject.lcsh | Parkinson's disease | en |
dc.title | Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence? | - |
dc.type | info:eu-repo/semantics/review | - |
dc.subject.lemac | Parkinson, Malaltia de | ca |
dc.subject.lcshes | Parkinson, Enfermedad de | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.doi | 10.1016/j.ensci.2017.06.004 | - |
dc.type.version | info:eu-repo/semantics/publishedVersion | - |
Apareix a les col·leccions: | Articles Articles cientÍfics |
Arxius per aquest ítem:
Arxiu | Descripció | Mida | Format | |
---|---|---|---|---|
levodopa.pdf | 299,03 kB | Adobe PDF | Veure/Obrir |
Comparteix:
Aquest ítem està subjecte a una llicència de Creative Commons Llicència Creative Commons